On the other hand, our results raise a caution for clinical contexts: Mcl-1 is a prominent target in cancer therapy (Glaser et al., 2012; Deng et al., 2024) because many tumors rely on Mcl-1 for survival and chemoresistance. The gene discussed is MCL1; the disease is cancer.